Serotypes and antimicrobial susceptibility of Streptococcus agalactiae;Serotipos y susceptibilidad antimicrobiana de Streptococcus agalactiae

Revista Medica de Chile

Volumn 132, Issue 5, 2004, Pages 549-555

  Martínez T, María Angélica ^a,e   Ovalle S, Alfredo ^b   Durán T, Claudia ^a   Reid S, Iván ^c   Urriola J, Gabriela ^d   Garay G, Beatriz ^d   Cifuentes D, Marcela ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^c Centro Médico CAPREDENA   (Chile)

^d HOSPITAL SAN JUAN DE DIOS   (Chile)

^e Departamento 403   (Chile)

Author keywords

Drug resistance, microbial; Serotyping; Streptococcus agalactiae

Indexed keywords

AMPICILLIN; CEFOTAXIME; CLINDAMYCIN; ERYTHROMYCIN; LINCOSAMIDE; MACROLIDE; PENICILLIN G; STREPTOGRAMIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRITIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG MECHANISM; HUMAN; NEWBORN SEPSIS; NONHUMAN; PREMATURE FETUS MEMBRANE RUPTURE; SEROTYPE; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS AGALACTIAE; URINARY TRACT INFECTION; VAGINITIS;

ADULT; AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PREGNANCY; SEPSIS; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TETRACYCLINE;

EID: 12544249867     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. BAKER CJ. Summary of the workshop on perinatal infections due to group B Streptococcus. J Infect Dis 1977; 136: 137-52.
2. CDC. Prevention of perinatal group B streptococ-cal disease. MMWR 2002/51 (RR11); 1-22.
3. OVALLE A, GÓMEZ R, MARTÍNEZ MA, ASPILLAGA C, DOLZ S. Infección vaginal y tratamiento del Streptococcus grupo B en embarazadas con factores universales de riesgo de infección. Resultados neonatales y factores de riesgo de infección neonatal. Rev Chil Obstet Ginecol 2002; 67: 467-75.
4. FARLEY MM, HARVEY RC, STULL T, SMITH JM, SCHUCHAT A, WENGER JD ET AL. A population based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328: 1807-11.
5. DE MOUY D, CAVALLO J-D, LECLERCQ R, FABRE R AND THE AFORCOPI-BIO NETWORK. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French Multiautor Study. Antimicrob Agents Chemother 2001; 45: 2400-2.
6. FERNÁNDEZ M, HICKMAN ME, BAKER CJ. Antimicrobial susceptibilities of Group B Streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother 1998; 42: 1517-9.
7. FITOUSSI F, LOUKIL C, GROS I, CLERMONT O, MARIANI P, BONACORSI S ET AL. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother 2001; 45: 1889-91.
8. KO WC, LEE HC, WANG LR, LEE CT, LIU AJ, WU JJ. Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight years period in Southern Taiwan. Eur J Clin Microbiol Infect Dis 2001; 20: 334-9.
9. MORALES WJ, DICKEY SS, BORNICK P, LIM DV. Change in antibiotic resistance of group B Streptococcus: Impact on intrapartum management. Am J Obstet Gynecol 1999; 181: 310-4.
10. MURDOCH DR, RELLER B. Antimicrobial susceptibilities of group B Streptococci isolated from patients with invasive disease: 10 years perspective. Antimicrob Agents Chemother 2001; 45: 3623-4.
11. PEARLMAN MD, PIERSON CL, FAIX RG. Frequent resistance in clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92: 258-61.
12. PORTILLO A, LANTERO M, OLARTE I, RUIZ-LARREA F, TORRES C. MLS resistance phenotypes and mechanisms in β-haemolytic group B, C and G Streptococcus isolated in La Rioja, Spain. J Antimicrob Chemother 2001; 47: 115-6.
13. UH Y, JANG IH, HWANG GY, YOON KJ, SONG W. Emerging erythromycin resistance among Group B Streptococci in Korea. Eur J Clin Microbiol Infect Dis 2001; 20: 52-4.
14. HARRISON LH, ELLIOTT JA, DWYER DM, LIBONATI JP, FERRIERI P, BILLMANN L ET AL. Serotype distribution of invasive group B streptococcal isolated in Maryland: implications for vaccine formulation. J Infect Dis 1998; 177: 998-1002.
15. LACHENAUER CS, KASPER DL, SHIMADA J, ICHIMAN Y, OHTSUKA H, KAKU M ET AL. Serotypes VI and VIII predominate among Group B Streptococci isolated from pregnant Japanese women. J Infect Dis 1999; 179: 1030-3.
16. MATSUBARA K, NISHIYAMA Y, KATAYAMA K, YAMAMOTO G, SUGIYAMA M, MURAI T ET AL. Change of antimicrobial susceptibility of group B streptococci over 15 years in Japan. J Antimicrob Chemother 2001; 48: 579-82.
17. BAKER CJ, PAOLETTI LC, WESSELS MR, GUTTORMSEN HK, RENCH MA, HICKMAN ME ET AL. Safety and immunogenicity of capsular polysaccharide tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142-50.
18. BAKER CJ, RENCH MA, FERNÁNDEZ M, PAOLETTI LC, KASPER DL, EDWARDS MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188: 66-73.
19. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. Performance Standards for Antimicrobial Susceptibility testing: Twelfth Informational Supplement. M100-S12; 22 (1) 2002. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. SUTCLIFFE J, TAIT-KAMRADT A, WONDRACK L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.
21. BINGEN E, FITOUSSI F, DORR C, COHEN R, TANNA A, GEORGE R ET AL. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 2000; 44: 1453-7.
22. LÄMMLER C, SCHWARZ S, WIBAWAN IWT, OTT E, BOPP B, MARTÍNEZ-TAGLE A. Comparison of streptococci of serological group B isolated from healthy carriers and active disease in Chile. J Med Microbiol 1995; 42: 161-4.
23. KALLIOLA S, VUOPIO-VARKILA J, TAKALA AK, ESKOLA J. Neonatal group B streptococcal disease in Finland: a ten years nationwide study. Pediatr Infect Dis J 1999; 18: 806-10.
24. KÄLLMAN J, SCHOLLIN J, HAKANSSON S, ANDERSSON A, KIHLSTRÖM E. Adherence of group B streptococci to human endothelial cells in vitro. APMIS 1993; 101: 403-8.
25. SHIGEOKA AO, ROTE NS, SANTOS JI, HILL HR. Assessment of the virulence factors of Group B streptococci: correlation with sialic acid content. J Infect Dis 1983; 147: 857-63.
26. TEXEIRA LA, FIGUEREIDO AM, FERREIRA BT, ALVES VM, NAGAO PE, ALVIANO CS ET AL. Sialic acid content and surface hydrophobicity of group B streptococci. Epidemiol Infect 1993; 110: 87-94.
27. ZALEZNIK DF, RENCH MA, HILLIER S, KROHN MA, PLATT R, LEE ML ET AL. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis 2000; 30: 276-81.
28. BLUMBERG HM, STEPHENS DS, MODANSKY M, ERWIN M, ELLIOT J, FACKLAM RR ET AL. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173: 365-73.
29. BAKER CJ, RENCH MA, MCINNES P. Immunization of pregnant women with group B streptococci type III capsular polysaccharide tetanus toxoid conjugate vaccine. Vaccine 2003; 21: 3468-72.
30. BELMAR C, ABARZÚA F, BECKER J, GUZMÁN AM, GARCÍA P, OYARZÚN E. Estudio de sensibilidad antimicrobiana de 183 cepas de Streptococcus agalactiae aisladas en región vagino-perineal de embarazadas en tercer trimestre. Rev Chile Obstet Ginecol 2002; 67: 106-9.
31. MARTÍNEZ MA, OVALLE A, GIGLIO MS, YURAC R, BECKER J, CAMPOS E ET AL. Sensibilidad antimicrobiana de Streptococcus agalactiae. Rev Chil Infect 1994; 11: 168-71.
32. ROBERTS MC, SUTCLIFFE J, COURVALIN P, JENSEN LB, ROOD J, SEPPALA H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43: 2823-30.